로딩 중…
StockDiggingStockDigging

DreamCIS, Inc.

223250· KOSDAQ
₩3,560-4.56%
2026-06-19

Price Chart

DreamCIS, Inc.-11.44%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap87.58B KRW
Revenue69.87B KRW
Net Income6.40B KRW
Total Assets162.93B KRW
Net Assets88.18B KRW
Employees358
Value
P/E13.68x
P/B0.99x
P/S1.25x
EV/EBITDA17.12x
FCF Yield13.52%
Profitability
ROE7.26%
ROA3.93%
Op. Margin6.37%
Revenue Growth22.87%
Earnings Growth-130.34%
Financial Health
Debt Ratio184.77%
Total Debt14.84B KRW
FCF11.84B KRW
Cash26.24B KRW
Current Ratio1.07x
Net Debt/EBITDA-2.56x
Performance
1Y Return-11.44%
1M Return-35.04%
From 52W High-58.80%
1Y MDD-53.71%
Trading
Volume157,435 shares
Foreign Own.50.27%
Per Share
EPS257 KRW
BPS3,206 KRW

Company Info

CEO 유정희
Employees 358
Founded 2000
HQ 서울특별시 종로구, KR

Dream CIS, a Clinical Research Organization (CRO) established in 2000, saw China's top CRO, Tigermed, acquire a stake in 2015. The company provides full-range services including clinical trial design, consulting, and monitoring, as well as comprehensive specialized services such as drug clinical trials, post-market surveillance, and statistical analysis. Leveraging Tigermed's global network, Dream CIS establishes a foundation for multinational clinical trial orders and secures competitiveness through the integration of standard operating procedures. Dream CIS was established in 2000 and is headquartered in Jongno-gu, Seoul.